Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.71
SLXP's Cash to Debt is ranked higher than
57% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SLXP: 0.71 )
SLXP' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: 0.71

Equity to Asset 0.25
SLXP's Equity to Asset is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. SLXP: 0.25 )
SLXP' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.89
Current: 0.25

0.25
0.89
Interest Coverage 4.41
SLXP's Interest Coverage is ranked lower than
51% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. SLXP: 4.41 )
SLXP' s 10-Year Interest Coverage Range
Min: 3.1   Max: 9999.99
Current: 4.41

3.1
9999.99
F-Score: 5
Z-Score: 3.03
M-Score: -3.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 29.10
SLXP's Operating margin (%) is ranked higher than
96% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. SLXP: 29.10 )
SLXP' s 10-Year Operating margin (%) Range
Min: -511.93   Max: 29.1
Current: 29.1

-511.93
29.1
Net-margin (%) 15.32
SLXP's Net-margin (%) is ranked higher than
87% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. SLXP: 15.32 )
SLXP' s 10-Year Net-margin (%) Range
Min: -475.24   Max: 16.17
Current: 15.32

-475.24
16.17
ROE (%) 19.31
SLXP's ROE (%) is ranked higher than
94% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SLXP: 19.31 )
SLXP' s 10-Year ROE (%) Range
Min: -208.17   Max: 19.31
Current: 19.31

-208.17
19.31
ROA (%) 4.86
SLXP's ROA (%) is ranked higher than
75% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. SLXP: 4.86 )
SLXP' s 10-Year ROA (%) Range
Min: -126.02   Max: 9.75
Current: 4.86

-126.02
9.75
ROC (Joel Greenblatt) (%) 36.37
SLXP's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. SLXP: 36.37 )
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3595.05   Max: 201.67
Current: 36.37

-3595.05
201.67
Revenue Growth (%) 34.20
SLXP's Revenue Growth (%) is ranked higher than
92% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SLXP: 34.20 )
SLXP' s 10-Year Revenue Growth (%) Range
Min: -2   Max: 112.5
Current: 34.2

-2
112.5
EBITDA Growth (%) 207.90
SLXP's EBITDA Growth (%) is ranked higher than
99% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. SLXP: 207.90 )
SLXP' s 10-Year EBITDA Growth (%) Range
Min: -28.2   Max: 207.9
Current: 207.9

-28.2
207.9
» SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SLXP Guru Trades in Q1 2013

Vanguard Health Care Fund 2,147,945 sh (+22.44%)
Pioneer Investments 544,300 sh (+1.19%)
Joel Greenblatt Sold Out
Steven Cohen 793,353 sh (-48.42%)
Jim Simons 53,719 sh (-85.48%)
» More
Q2 2013

SLXP Guru Trades in Q2 2013

Joel Greenblatt 127,495 sh (New)
Paul Tudor Jones 4,300 sh (New)
Jim Simons 338,319 sh (+529.79%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Pioneer Investments 371,100 sh (-31.82%)
Steven Cohen 465,300 sh (-41.35%)
» More
Q3 2013

SLXP Guru Trades in Q3 2013

Paul Tudor Jones 8,400 sh (+95.35%)
Pioneer Investments 452,933 sh (+22.05%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons 262,100 sh (-22.53%)
Steven Cohen 230,379 sh (-50.49%)
» More
Q4 2013

SLXP Guru Trades in Q4 2013

Jim Simons 268,519 sh (+2.45%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Pioneer Investments 410,439 sh (-9.38%)
Steven Cohen 97,861 sh (-57.52%)
Paul Tudor Jones 3,200 sh (-61.9%)
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-09-30 Sold Out 0.36%$65.73 - $75.54 $ 109.0758%0
Joel Greenblatt 2013-06-30 New Buy0.36%$47.72 - $66.83 $ 109.0791%127495
Joel Greenblatt 2013-03-31 Sold Out 0.15%$40.472 - $51.37 $ 109.07127%0
Vanguard Health Care Fund 2013-03-31 Add 22.44%0.08%$40.472 - $51.37 $ 109.07127%2147945
Joel Greenblatt 2012-12-31 Add 75.81%0.06%$37.97 - $42.9 $ 109.07167%63399
Joel Greenblatt 2012-09-30 New Buy0.1%$41.92 - $55.65 $ 109.07130%36061
John Paulson 2011-09-30 Sold Out 0.2056%$26.18 - $40.9 $ 109.07230%0
Vanguard Health Care Fund 2011-09-30 Add 55.43%0.09%$26.18 - $40.9 $ 109.07230%1554300
John Paulson 2011-06-30 Add 971.43%0.19%$34.69 - $40.57 $ 109.07188%1500000
George Soros 2011-06-30 Sold Out $34.69 - $40.57 $ 109.07188%0
John Paulson 2011-03-31 New Buy0.01%$31.61 - $48.03 $ 109.07181%140000
George Soros 2011-03-31 Reduce -95.44%$31.61 - $48.03 $ 109.07181%5700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 50.30
SLXP's P/E(ttm) is ranked lower than
51% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. SLXP: 50.30 )
SLXP' s 10-Year P/E(ttm) Range
Min: 12.19   Max: 110.56
Current: 50.3

12.19
110.56
P/B 9.10
SLXP's P/B is ranked lower than
68% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. SLXP: 9.10 )
SLXP' s 10-Year P/B Range
Min: 1.01   Max: 11.53
Current: 9.1

1.01
11.53
P/S 7.60
SLXP's P/S is ranked lower than
68% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. SLXP: 7.60 )
SLXP' s 10-Year P/S Range
Min: 1.28   Max: 12.23
Current: 7.6

1.28
12.23
PFCF 17.70
SLXP's PFCF is ranked higher than
83% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. SLXP: 17.70 )
SLXP' s 10-Year PFCF Range
Min: 5.08   Max: 371
Current: 17.7

5.08
371
EV-to-EBIT 27.00
SLXP's EV-to-EBIT is ranked higher than
55% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. SLXP: 27.00 )
SLXP' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 99.5
Current: 27

10.4
99.5
Shiller P/E 308.90
SLXP's Shiller P/E is ranked lower than
72% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. SLXP: 308.90 )
SLXP' s 10-Year Shiller P/E Range
Min: 240.14   Max: 4937
Current: 308.9

240.14
4937

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 42.30
SLXP's Price/Tangible Book is ranked lower than
86% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SLXP: 42.30 )
SLXP' s 10-Year Price/Tangible Book Range
Min: 2.57   Max: 34.86
Current: 42.3

2.57
34.86
Price/DCF (Projected) 4.00
SLXP's Price/DCF (Projected) is ranked lower than
54% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SLXP: 4.00 )
SLXP' s 10-Year Price/DCF (Projected) Range
Min: 3.31   Max: 76.06
Current: 4

3.31
76.06
Price/Median PS Value 1.50
SLXP's Price/Median PS Value is ranked lower than
53% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SLXP: 1.50 )
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 3.11
Current: 1.5

0.32
3.11
Price/Graham Number 9.50
SLXP's Price/Graham Number is ranked lower than
80% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. SLXP: 9.50 )
SLXP' s 10-Year Price/Graham Number Range
Min: 1.89   Max: 7.82
Current: 9.5

1.89
7.82
Earnings Yield (Greenblatt) 3.70
SLXP's Earnings Yield (Greenblatt) is ranked higher than
62% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SLXP: 3.70 )
SLXP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 9.7
Current: 3.7

1
9.7
Forward Rate of Return (Yacktman) 0.71
SLXP's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. SLXP: 0.71 )
SLXP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.5   Max: 1
Current: 0.71

-8.5
1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:XP2.Germany
Salix Pharmaceuticals, Ltd. incorporated in the state of Delaware. It is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The Company's 'search and development' efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by non-invasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, low-volume liquid bowel prep with the effectiveness of high-volume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. Anusol-HC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide